top of page
Peera Hemarajara M.D. Ph.D.

Peer-reviewed Journals


  1. Hemarajata, P. and J. Versalovic (2012) “Intestinal Lactobacillus reuteri: Partners and Beneficial Microbes.” Old Herborn University Seminar Monograph 25. Article 3.

  2. Thomas, C. M., T. Hong, van Pijkeren, J. P., Hemarajata, P., Trinh, D. V., Hu, W., Britton, R. A., Kalkum, M. and Versalovic, J(2012). "Histamine Derived from Probiotic Lactobacillus reuteri Suppresses TNF via Modulation of PKA and ERK Signaling." PLoS One 7(2): e31951.

  3. Hemarajata, P. and J. Versalovic (2013). "Effects of Probiotics on Gut Microbiota: Mechanisms of Intestinal Immunomodulation and Neuromodulation." Therap Adv Gastroenterol 6(1): 39-51.

  4. Devaraj, S., P. Hemarajata and Versalovic, J (2013). "The Human Gut Microbiome and Body Metabolism: Implications for Obesity and Diabetes." Clin Chem.

  5. Hemarajata, P., C. Gao, K. J. Pflughoeft, C. M. Thomas, D. M. Saulnier, J. K. Spinler and J. Versalovic (2013). "Lactobacillus reuteri-specific immunoregulatory gene rsiR modulates histamine production and immunomodulation by Lactobacillus reuteri." J Bacteriol 195(24): 5567-5576.

  6. Hemarajata, P., J. K. Spinler, M. A. Balderas and J. Versalovic (2014). "Identification of a proton-chloride antiporter (EriC) by Himar1 transposon mutagenesis in Lactobacillus reuteri and its role in histamine production." Antonie Van Leeuwenhoek 105(3): 579-592.

  7. Spinler J, P Hemarajata, J Versalovic. 2015. “Microbial Genomics and Pathogen Discovery.” p 238-251. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, 11th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch16

  8. Hemarajata, P., K. Adachi, L. Ramirez-Avila, R.M. Humphries (2015). “Staphylococcus saprophyticus Bacteremia in a Pediatric Patient with Central Venous Catheter-associated Infection.” Clinical Microbiology Newsletter 38 (19) , 153-157.

  9. Hemarajata, P., S. Yang, J. Hindler and R. M. Humphries (2015). "Development of a novel real-time PCR assay with high-resolution melt analysis to detect and differentiate OXA-48-like beta-lactamases in carbapenem-resistant Enterobacteriaceae." (2015) Antimicrob Agents Chemother 59 (9), 5574-5580.

  10. Yang, S. S., Hemarajata, P., Hindler, J., Ward, K., Li, F., Adisetiyo, H., ... & Humphries, R. M. (2015, December). Identification of Klebsiella pneumoniae Producing OXA-232 and CTX-M-15 by Whole-Genome Sequencing Analysis. Open Forum Infectious Diseases (Vol. 2, No. suppl 1, p. 105). Oxford University Press.

  11. Baghdadi, J, P Hemarajata et al. (2015) "First Report of Ventriculoperitoneal Shunt Infection due to Cyberlindnera fabianii." Case reports in infectious diseases.

  12. Humphries, R.M., S. Yang, P Hemarajata, K. Ward, J.A. Hindler, S.A. Miller, A. Gregson (2015). “First report of ceftazidime-avibactam resistance in a KPC-expressing Klebsiella pneumonia.” Antimicrob Agents Chemother. 59.10: 6605-6607.

  13. Yang, S., P. Hemarajata et al. (2015) “Investigation of a Suspected Nosocomial Transmission of blaKPC-3-Mediated Carbapenem Resistant Klebsiella pneumoniae by Whole Genome Sequencing.” Diagnostic Microbiology and Infectious Disease 84(4), 337-342.

  14. Hemarajata, P., Yang, S., Soge, O. O., Humphries, R. M., & Klausner, J. D. (2016). Performance and Verification of a Real-Time PCR Assay Targeting the gyrA Gene for Prediction of Ciprofloxacin Resistance in Neisseria gonorrhoeae. Journal of clinical microbiology, 54(3), 805-808.

  15. Hemarajata, P. (2016) “Screening Tests for Detection of High-Level Mupirocin Resistance in Staphylococcus aureus.”, p 5.8.1-5.8.4. In Clinical Microbiology Procedures Handbook, Fourth Edition. ASM Press, Washington, DC. Editor: Amy L. Leber, doi: 10.1128/9781555818814.ch5.8

  16. Yang, S., McHardy, I. H., Hemarajata, P., Wu, M. T., & Garner, O. B. (2016). Microbial Recovery from Clot Activating Vacutainers®. Diagnostic Microbiology and Infectious Disease. 85 (4), 395-397.

  17. Kim, S., Russell, D., Mohamadnejad, M., Makker, J., Sedarat, A., Watson, R.R., Yang, S., Hemarajata, P., Humphries, R., Rubin, Z. and Muthusamy, V.R., (2016) Risk factors associated with the transmission of carbapenem-resistant Enterobacteriaceae via contaminated duodenoscopes. Gastrointestinal endoscopy, 83(6), pp.1121-1129.

  18. Thomas, C.M., Saulnier, D., Spinler, J.K., Hemarajata, P., Gao, C., Jones, S.E., Grimm, A., Balderas, M.A., Burstein, M.D., Morra, C. and Roeth, D., (2016). FolC2‐mediated folate metabolism contributes to suppression of inflammation by probiotic Lactobacillus reuteri. MicrobiologyOpen 5.5:802-818.

  19. Antony, K., Hemarajata, P., Chen, J., Morris, J., Cook C., Masalas, D., Gedminas, M., Brown, A., Versalovic, J., Aagaard K, (2016). Generation and Validation of a Universal Perinatal Database and Biospecimen Repository: PeriBank. Journal of Perinatology 36(11), 921-929.

  20. Hemarajata, P., Baghdadi, J. D., Hoffman, R., & Humphries, R. M. (2016). Burkholderia pseudomallei: challenges for the clinical microbiology laboratory. Journal of Clinical Microbiology, 54(12), 2866-2873.

  21. Allan-Blitz, L. T., Humphries, R. M., Hemarajata, P., Bhatti, A., Pandori, M. W., Siedner, M. J., & Klausner, J. D. (2016). Implementation of a Rapid Genotypic Assay to Promote Targeted Ciprofloxacin Therapy of Neisseria gonorrhoeae in a Large Health System. Clinical Infectious Diseases, 64 (9), 1268-1270.

  22. Hemarajata, P. & Humphries, R. M. (2017). Reply to “Burkholderia pseudomallei: Challenges for the Clinical Microbiology Laboratory—a Response from the Front Line”. Journal of Clinical Microbiology, 55(3), 983-984.

  23. Yang, Shangxin, Hemarajata, P.,et al. (2017) "Evolution and Transmission of Carbapenem-resistant Klebsiella pneumoniae Expressing the blaoxa-232 Gene During an Institutional Outbreak Associated With Endoscopic Retrograde Cholangiopancreatography." Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 64.7: 894-901.

  24. Humphries, R. M. & Hemarajata, P. (2017) "Resistance to ceftazidime-avibactam in Klebsiella pneumoniae due to porin mutations and the increased expression of KPC-3." Antimicrobial Agents and Chemotherapy 61.6: e00537-17.

  25. Nelson, K, Hemarajata, P.,et al. (2017). Resistance to ceftazidime-avibactam is due to transposition of KPC in a porin-deficient strain of Klebsiella pneumoniae with increased efflux activity. Antimicrobial agents and chemotherapy 61.10: e00989-17.

  26. Humphries, R.M., Yang, S., Kim, S., Muthusamy, V.R., Russell, D., Trout, A.M., Zaroda, T., Cheng, Q.J., Aldrovandi, G., Uslan, D.Z., Hemarajata, P., Rubin, Z.A., (2017). Duodenoscope-Related Outbreak of a Carbapenem-Resistant Klebsiella pneumoniae Identified Using Advanced Molecular Diagnostics. Clinical Infectious Diseases. cix527,

  27. Dreyer, S.D., Hemarajata, P., Hogeling, M., Henderson, G.P. (2017) “Pediatric Vaccine-Strain Herpes Zoster, a Case Series” Pediatric Dermatology. 00:1–2.

  28. Bhatti A.A., Allan-Blitz, L., Castrejon M., Humphries R.M., Hemarajata, P., Klausner J.D. (2017) “Epidemiology of Neisseria gonorrhoeae Gyrase A Genotype, Los Angeles” Emerging Infectious Diseases. 23.9 (2017): 1581

  29. Allan-Blitz, L. T., Hemarajata, P. et al. (2017) “A Cost Analysis of Gyrase A Testing and Targeted Ciprofloxacin Therapy vs. Recommended Two-Drug Therapy for Neisseria gonorrhoeae Infection” Sexually Transmitted Diseases 45 (2), 87-91.

  30. Kanata, LW., Hemarajata, P., Olusegun, S.O., Humphries, R.M., Klausner, J.D. (2017) “Real-Time PCR Targeting penA Mosaic XXXIV Type for Prediction of Extended-Spectrum Cephalosporins Susceptibility in Clinical Neisseria gonorrhoeae Isolates” Antimicrobial Agents and Chemotherapy. 61 (11), e01339-17.

  31. Yang, S., Hemarajata, P. et al. (2018) “Unusual Carbapenem Resistant but Ceftriaxone and Cefepime Susceptible Klebsiella oxytoca Isolated from a Blood Culture: Case Report and Whole-genome Sequencing Investigation.” IDCases 11:9-11.

  32. Allan-Blitz, Lao-Tzu, Hemarajata, P. et al. (2017) "Ciprofloxacin May be Efficacious in Treating Wild-Type Gyrase A Genotype Neisseria gonorrhoeae Infections." Sexually Transmitted Diseases 45 (4), e18.

  33. Hemarajata, P., Amick, T. et al. (2018) “Selection of Hyperproduction of SME-1 and AmpC in A Carbapenem-Resistant Serratia marcescens During Antibiotic Therapy.” Journal of Antimicrobial Chemotherapy 73 (5), 1256-1262.

  34. Campeau, S. A., Schuetz, A. N., Kohner, P., Arias, C. A., Hemarajata, P., Dien Bard, J., & Humphries, R. M. (2018). “Variability of daptomycin minimum inhibitory concentrations for Enterococcus faecium when measured by reference broth microdilution and gradient diffusion tests.” Antimicrobial Agents and Chemotherapy. doi:10.1128/AAC.00745-18

  35. Hakki, M., Humphries, R. M., Hemarajata, P., Tallman, G. B., Shields, R. K., Mettus, R. T., & Lewis, J. S. (2018). Fluoroquinolone prophylaxis selects for meropenem non-susceptible Pseudomonas aeruginosa in patients with hematologic malignancies and hematopoietic-cell transplant recipients. Clinical Infectious Diseases.

  36. Allan-Blitz, L.T., Ellis, O.L., Bolan, R., Hemarajata, P., Humphries, R.M., Shahkolahi, A., McGrath, M. and Klausner, J.D. (2019) "The Frequency of Discordant Gyrase A Genotypes Among Cases of Multiple Neisseria gonorrhoeae Infections at Different Anatomic Sites." Sexually transmitted diseases 46.1: e3-e4.

  37. Hemarajata, P. and Humphries. R.M. (2019) "Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2." Journal of Antimicrobial Chemotherapy.

  38. Ellis, Olivia, Hemarajata, P., et al. (2019) "A multisite implementation of a real-time polymerase chain reaction assay to predict ciprofloxacin susceptibility in Neisseria gonorrhoeae." Diagnostic microbiology and infectious disease.

bottom of page